Overview
Ipamorelin and sermorelin both release growth hormone, but they are different kinds of compound. Ipamorelin is a pentapeptide that acts through a GHRP-like (ghrelin-type) receptor (Raun 1998). Sermorelin is a 29 amino acid analogue of growth hormone-releasing hormone (GHRH) (Prakash 1999). No source checked compares them head to head, so this page sets the two records side by side. It is background for research use only.
Side by side
| Point | Detail | Source |
|---|---|---|
| Class | Ipamorelin: GHRP-receptor agonist (GH secretagogue). Sermorelin: GHRH analogue. | Raun 1998, Prakash 1999 |
| Preclinical potency | Ipamorelin: EC50 1.3 nmol/L for GH release from rat pituitary cells (Emax 85%); ED50 2.3 nmol/kg in conscious swine. | Raun 1998 |
| Selectivity | Ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation in swine, even at more than 200-fold the GH ED50. | Raun 1998 |
| Human pharmacokinetics | Ipamorelin: terminal half-life 2 hours, clearance 0.078 L/h/kg in healthy men. Sermorelin: no half-life reported in the sources checked. | Gobburu 1999 |
| Clinical studies | Ipamorelin: 117 patients after bowel resection, no significant difference from placebo in time to first solid meal (25.3 vs 32.6 hours, p=0.15). Sermorelin: 18 children, 8 with gains above 2 cm/year. | Beck 2014, Ross 1987 |
| Antibodies | Sermorelin: anti-GHRH antibodies in 14 of 18 children, with no apparent effect on growth. Not reported for ipamorelin in the sources checked. | Ross 1987 |
What each record covers
For ipamorelin the evidence is preclinical potency and selectivity work (Raun 1998), a human pharmacokinetic study (Gobburu 1999) and one small proof-of-concept trial (Beck 2014). For sermorelin it is a review of pediatric diagnostic and growth studies (Prakash 1999) and an early 18-child trial (Ross 1987). The two compounds were studied for different purposes, so their results are not interchangeable. See the ipamorelin vs GHRP-6 comparison and the sermorelin overview.
What the sources do not show
- No head-to-head study of ipamorelin and sermorelin appears in the sources checked.
- No source checked tests the two compounds together, so no combination claim is made.
- The potency figures for ipamorelin come from rat and swine experiments and do not translate directly to other models.
Related research products and tools
- Ipamorelin peptide vial
- Sermorelin peptide vial
- Ipamorelin nasal spray
- Sermorelin nasal spray
- Ipamorelin calculator
- Sermorelin calculator
Frequently Asked Questions
What is the difference between ipamorelin and sermorelin?
Ipamorelin acts through a GHRP-like receptor, while sermorelin is a GHRH analogue (Raun 1998, Prakash 1999).
Does ipamorelin raise cortisol?
In swine it did not release ACTH or cortisol at levels significantly different from GHRH stimulation (Raun 1998).
Has ipamorelin been compared with sermorelin?
Not head to head in the sources checked.
Key References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999. PubMed 10496658
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PubMed 25331030
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed 18031173
- Ross RJ, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet. 1987. PubMed 2879138
For research use only. Not for human consumption.